Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Georges El Hachem, Andrea Gombos & Ahmad Awada. (2021) Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. Expert Review of Anticancer Therapy 21:1, pages 81-92.
Read now
Read now
Articles from other publishers (9)
Michelino De Laurentiis, Roberta Caputo, Manuelita Mazza, Mauro Mansutti, Riccardo Masetti, Zelmira Ballatore, Rosalba Torrisi, Andrea Michelotti, Alberto Zambelli, Antonella Ferro, Daniele Generali, Patrizia Vici, Luigi Coltelli, Alessandra Fabi, Paolo Marchetti, Alberto Ballestrero, Simon Spazzapan, Antonio Frassoldati, Maria Giuseppina Sarobba, Donatella Grasso & Claudio Zamagni. (2022) Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study. Targeted Oncology 17:6, pages 615-625.
Crossref
Crossref
Chuanhui Huang, Shan Wang & Weifeng Ma. (2022) Design, Synthesis, and Antitumor Activity of New N4-Alkyl-N2-Phenyl-Pyrrolo[3,2-d]Pyrimidine-2,4-Diamine Derivatives as CDK6 Inhibitors. Russian Journal of Bioorganic Chemistry 48:3, pages 557-564.
Crossref
Crossref
Madhu Sharma, Naresh Mittapelly, Venkatesh Teja Banala, Sandeep Urandur, Shalini Gautam, Disha Marwaha, Nikhil Rai, Neha Singh, Ashutosh Gupta, Kalyan Mitra & Prabhat Ranjan Mishra. (2022)
Amalgamated Microneedle Array Bearing Ribociclib-Loaded Transfersomes Eradicates Breast Cancer
via
CD44 Targeting
. Biomacromolecules 23:3, pages 661-675.
Crossref
Crossref
Zhongjie Fei & Mehdi Yoosefian. (2021) Design and development of polymeric micelles as nanocarriers for anti-cancer Ribociclib drug. Journal of Molecular Liquids 329, pages 115574.
Crossref
Crossref
Elena De Mattia, Erika Cecchin, Michela Guardascione, Luisa Foltran, Tania Di Raimo, Francesco Angelini, Mario D’Andrea & Giuseppe Toffoli. (2019) Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World Journal of Gastroenterology 25:29, pages 3870-3896.
Crossref
Crossref
Melania Poratti & Giovanni Marzaro. (2019) Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. European Journal of Medicinal Chemistry 172, pages 143-153.
Crossref
Crossref
Syed Mohd. Danish Rizvi, Abdulaziz Arif A. Alshammari, Waleed Abdullah Almawkaa, Abo Bakr F. Ahmed, Ahmed Katamesh, Ahmed Alafnan, Tariq J. Almutairi & Rakan F. Alshammari. (2019) An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication. 3 Biotech 9:3.
Crossref
Crossref
Marco Fiorillo, Federica Sotgia & Michael P. Lisanti. (2019) “Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy. Frontiers in Oncology 8.
Crossref
Crossref
Georges El Hachem, Andrea Gombos & Ahmad Awada. (2019) Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer. F1000Research 8, pages 591.
Crossref
Crossref